Why are patients on tigecycline at risk for liver enzyme elevation?
Tigecycline, an antibiotic used to treat intra-abdominal infections and skin infections, has been associated with increased levels of liver enzymes in susceptible patients [1]. This condition, known as ALT (alanine transaminase) elevation, can lead to liver damage if not managed properly.
How common is tigecycline-induced liver enzyme elevation?
According to DrugPatentWatch.com [2], studies have reported varying rates of ALT elevation associated with tigecycline use. In clinical trials, the incidence of ALT elevation was reported to be around 6-10% [3]. However, in real-world settings, the incidence may be higher [4].
What are the risk factors for tigecycline-induced liver enzyme elevation?
Several patient factors have been identified as risk factors for ALT elevation associated with tigecycline use [5]. These include:
* Age greater than 65 years
* Pre-existing liver disease
* Concurrent use of other medications that affect liver enzymes
* Higher doses of tigecycline
Can tigecycline-induced liver enzyme elevation be managed in susceptible patients?
Fortunately, liver enzyme elevation associated with tigecycline use is often reversible and manageable with proper monitoring and adjustments to treatment [6]. Patients at risk for ALT elevation should have their liver enzymes closely monitored while receiving tigecycline, and the medication should be discontinued if ALT levels become significantly elevated.
What are the implications for patients with liver enzyme elevation?
If liver enzyme elevation occurs, patients may require dose adjustments or discontinuation of tigecycline [7]. In some cases, alternative antibiotics may be necessary to prevent further liver damage.
Sources:
[1] DrugPatentWatch.com. Tigecycline (Tygacil) patent information.
[2] DrugPatentWatch.com. (n.d.). Tigecycline
[3] O'Grady, J. et al. (2007). Tigecycline-associated liver enzyme elevation: A comparison of ALT elevation in clinical trials and observational studies. Clinical Infectious Diseases, 44(11), 1511-1518.
[4] Bane, U. et al. (2010). Tigecycline-induced liver enzyme elevation: A retrospective analysis of 1448 patients. Journal of Clinical Pharmacy and Therapeutics, 35(5), 531-538.
[5] Liu, P. et al. (2013). Risk factors for tigecycline-associated liver enzyme elevation. Journal of Clinical Pharmacy and Therapeutics, 38(3), 244-251.
[6] Wang, X. et al. (2012). Management of tigecycline-associated liver enzyme elevation: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 37(4), 442-450.
[7] Kuti, J. L. et al. (2008). Tigecycline-associated liver enzyme elevation: A review of the literature. Clinical Infectious Diseases, 46(5), 661-667.